Yi Fan Wu

Ms. Yi Fan Wu

School of Public Health, University of Alberta, Edmonton, Alberta, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
EWEmily Walker
Emily Walker
YZYiling Zhou
Yiling Zhou
YWYi Fan Wu
Yi Fan Wu
JLJiaqi Liu
Jiaqi Liu
SCSeth A Climans
Seth A Climans
YYYan Yuan
Yan Yuan
Primary central nervous system (CNS) tumours are heterogeneous, with different treatment pathways and prognoses depending on their histological and molecular classification. Due to their anatomical location, all CNS tumours, regardless of malignancy, can be debilitating. We used vital statistics linked to Canadian Cancer Registry data to estimate the age-standardized incidence rates (ASIR), Kaplan–Meier survival rates (SR), and limited-duration prevalence proportions (PP) of 25 histology-specific CNS tumour groups that were classified based on site and histology. During 2010–2017, 45,115 patients were diagnosed with 47,085 primary CNS tumours, of which 19.0% were unclassified. The average annual ASIR was 21.48/100,000 person-years and did not vary by sex. The ASIR increased with age, particularly for meningioma, unclassified tumours, and glioblastoma. The eight-year PP was 102.1/100,000 persons (index date 1 January 2018). The most common histology was meningioma (ASIR: 5.19; PP: 31.6). The overall five-year SR among 51,310 patients diagnosed during 2008–2017 was 57.2% (95% CI: 56.8–57.7%). SRs varied by tumour behaviour, histology, and patient age, with the lowest SR among glioblastoma patients (5-year SRs ranged from 1.3–25.7%). For non-malignant tumours, the 5-year SRs ranged from 37.4–100%. We provide the most up-to-date histology-specific surveillance estimates for primary CNS tumours in Canada.

29 May 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
YWYi Fan Wu
Yi Fan Wu
EWEmily Walker
Emily Walker
YYYan Yuan
Yan Yuan
Canada’s decentralized healthcare system may lead to regional disparities in survival among Canadians diagnosed with central nervous system (CNS) tumours. We identified 50,670 patients diagnosed with a first-ever primary CNS tumour between 2008 and 2017 with follow-up until 31 December 2017. We selected the four highest incidence histologies and used proportional hazard regression to estimate hazard ratios (HRs) for five regions (British Columbia, Prairie Provinces, Ontario, Atlantic Provinces and the Territories), adjusting for sex, tumour behaviour and patient age. Ontario had the best survival profile for all histologies investigated. The Atlantic Provinces had the highest HR for glioblastoma (HR = 1.26, 95% CI: 1.18–1.35) and malignant glioma not otherwise specified (NOS) (Overall: HR = 1.87, 95% CI:1.43–2.43; Pediatric population: HR = 2.86, 95% CI: 1.28–6.39). For meningioma, the Territories had the highest HR (HR = 2.44, 95% CI: 1.09–5.45) followed by the Prairie Provinces (HR = 1.52, 95% CI: 1.38–1.67). For malignant unclassified tumours, the highest HRs were in British Columbia (HR = 1.45, 95% CI: 1.22–1.71) and the Atlantic Provinces (HR = 1.40, 95% CI: 1.13–1.74). There are regional differences in the survival of CNS patients at the population level for all four specific histological types of CNS tumours investigated. Factors contributing to these observed regional survival differences are unknown and warrant further investigation.

1 July 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
YWYi Fan Wu
Yi Fan Wu
YYYan Yuan
Yan Yuan
EWEmily V Walker
Emily V Walker
Health care in Canada is delivered on a provincial or territorial level. The objective of our population-based study was to investigate regional differences in survival among Canadians diagnosed with central nervous system (CNS) tumours. We identified 50,670 patients diagnosed with a first-ever primary CNS tumour between 2008 and 2017 with follow-up until December 31, 2017 (excluding Quebec) from the Canadian Cancer Registry linked to vital statistics. We selected the four highest incidence histologies and used Cox proportional hazards regression to estimate hazard ratios (HRs) for regions in Canada (British Columbia, the Prairie provinces, Ontario, the Atlantic provinces, and the Territories) adjusting for sex and tumour behaviour (malignant vs. non-malignant), and stratified by patient age. Ontario was the reference region and had the best survival profile for all histologies investigated. The Atlantic provinces had the highest HR for glioblastomas (HR=1.26, 95% CI:1.18-1.35), gliomas not otherwise specified (NOS) (Overall: HR=1.87, 95% CI:1.43-2.43; Pediatric population: HR=2.86, 95% CI:1.28-6.39) and unclassified tumours (HR=1.95, 95% CI:1.63-2.34). For meningiomas, the Territories had the highest HR (HR=2.44, 95% CI:1.09-5.45) followed by the Prairie provinces (HR=1.52, 95% CI:1.38-1.67). Our findings suggest that regional differences in survival may exist for patients with specific histological subtypes of CNS tumours at the population level. Whether the differential capture of non-malignant tumours across regions, tumour misclassification, or both contributes to the observed regional survival differences warrants further investigation.

23 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
YWYi Fan Wu
Yi Fan Wu
EWEmily Walker
Emily Walker
YYYan Yuan
Yan Yuan
Health care in Canada is managed by provinces/territories. We investigated regional differences in survival among Canadians diagnosed with central nervous system (CNS) tumours. We identified 50,670 patients diagnosed with a first-ever primary CNS tumour between 2008 and 2017 with follow-up until December 31, 2017. We selected the four highest incidence histologies and used proportional hazards regression to estimate hazard ratios (HRs) for five regions (British Columbia, Prairie provinces, Ontario, Atlantic provinces and the Territories), adjusting for sex, tumour behaviour and patient age. Ontario had the best survival profile for all histologies investigated. The Atlantic provinces had the highest HR for glioblastoma (HR=1.26, 95% CI:1.18-1.35) and malignant glioma not otherwise specified (NOS) (Overall: HR=1.87, 95% CI:1.43-2.43; Pediatric population: HR=2.86, 95% CI:1.28-6.39). For meningioma, the Territories had the highest HR (HR=2.44, 95% CI:1.09-5.45) followed by the Prairie provinces (HR=1.52, 95% CI:1.38-1.67). For malignant unclassified tumours, the highest HRs were in British Columbia (HR=1.45, 95% CI:1.22-1.71) and the Atlantic provinces (HR=1.40, 95% CI:1.13-1.74). There are regional differences in the survival of CNS patients at the population level for all four specific histological types of CNS tumours investigated. Factors contributing to these observed regional survival differences are unknown and warrant further investigation.